IMGN853在卵巢癌联合治疗中诱导自噬性细胞死亡。
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer.
作者信息
Chelariu-Raicu Anca, Vu Thanh Chung, Umamaheswaran Sujanitha, Stur Elaine, Hanjra Pahul, Han Yunah, Hu Min, Lin Jerome, Lawson Barrett C, Liu Jinsong, Sood Anil K, Wen Yunfei
机构信息
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
出版信息
Cancer Res Commun. 2025 Mar 1;5(3):512-526. doi: 10.1158/2767-9764.CRC-24-0215.
FOLR1 is heterogeneously overexpressed in epithelial ovarian cancer. We examined the combined effects of the anti-FOLR1 antibody-drug conjugate (IMGN853) with other drugs, including topotecan, anti-VEGF-A antibody, and olaparib. These findings could contribute to the continued development of IMGN853 in the treatment of ovarian cancer.
叶酸受体1（FOLR1）在上皮性卵巢癌中呈异质性过表达。我们研究了抗FOLR1抗体药物偶联物（IMGN853）与其他药物（包括拓扑替康、抗血管内皮生长因子A（VEGF-A）抗体和奥拉帕利）联合使用的效果。这些发现可能有助于IMGN853在卵巢癌治疗中的持续研发。
Zotero 插件